New electronic medical device for treating leg pain

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it has released a new way to deliver the impulses of the ReBuilder for pain.

Physicians all over the U.S. are now using the ReBuilder as their first choice for the treatment of leg pain. Pain can be caused by many things, including Arthritis. Many of them are not registered with Medicare so that they can provide the ReBuilder to their patients with little or no out of pocket cost to the patient.

"While the ReBuilder has a 20 year proven track record for the treatment of chronic hand pain from neuropathy," said David Phillips, Ph.D. CEO., "some patients have used it successfully to treat their pain that originated from arthritis."

Additionally, Dr. Phillips reports: "This new way to administer the ReBuilder's signals is with a special conductive glove that replaces the common electrodes that have been used in the past."

Finally, Dr. Phillips told reporters today: "Now a patient with pain from arthritis can put on these form fitting gloves, turn on his ReBuilder, read his morning paper, and at the end of the 10 minute session he can feel the relief and can go about his normal activities symptom free. Now that Medicare covers the ReBuilder for pain, we expect another jump in sales."

 http://www.rebuildermedical.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Genetic risk factors for long-COVID uncovered in a large multi-ethnic study